Search Results - "Gray, Elin S"

Refine Results
  1. 1

    Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? by Asante, Du-Bois, Calapre, Leslie, Ziman, Melanie, Meniawy, Tarek M., Gray, Elin S.

    Published in Cancer letters (01-01-2020)
    “…Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical…”
    Get full text
    Journal Article
  2. 2

    Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes by Wibmer, Constantinos Kurt, Bhiman, Jinal N, Gray, Elin S, Tumba, Nancy, Abdool Karim, Salim S, Williamson, Carolyn, Morris, Lynn, Moore, Penny L

    Published in PLoS pathogens (01-10-2013)
    “…Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to…”
    Get full text
    Journal Article
  3. 3

    Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies by Calapre, Leslie, Giardina, Tindaro, Beasley, Aaron B., Reid, Anna L., Stewart, Colin, Amanuel, Benhur, Meniawy, Tarek M., Gray, Elin S.

    Published in Scientific reports (06-01-2023)
    “…Plasma circulating tumour DNA (ctDNA) has been suggested to be a viable biomarker of response to treatment in patients with high grade serous ovarian carcinoma…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients by McEvoy, Ashleigh C, Warburton, Lydia, Al-Ogaili, Zeyad, Celliers, Liesl, Calapre, Leslie, Pereira, Michelle R, Khattak, Muhammad A, Meniawy, Tarek M, Millward, Michael, Ziman, Melanie, Gray, Elin S

    Published in BMC cancer (09-07-2018)
    “…Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always…”
    Get full text
    Journal Article
  6. 6

    Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis by Acheampong, Emmanuel, Abed, Afaf, Morici, Michael, Bowyer, Samantha, Amanuel, Benhur, Lin, Weitao, Millward, Michael, Gray, Elin S

    Published in Cells (Basel, Switzerland) (31-10-2020)
    “…Antibodies against programmed death-1 (PD-1), and its ligand, (PD-L1) have been approved recently for the treatment of small-cell lung cancer (SCLC). Although…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study by Kim, Jin-Soo, Taaffe, Dennis R, Galvão, Daniel A, Clay, Timothy D, Redfern, Andrew D, Gray, Elin S, Newton, Robert U

    Published in BMC cancer (01-07-2024)
    “…Physical activity is associated with improved disease progression and cancer-specific survival in patients with prostate cancer (PCa). However, the mechanisms…”
    Get full text
    Journal Article
  10. 10

    Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report by Calapre, Leslie, Warburton, Lydia, Millward, Michael, Gray, Elin S

    Published in BMC cancer (14-11-2019)
    “…Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. The presence…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients by Asante, Du-Bois, Mohan, Ganendra R. K. A., Acheampong, Emmanuel, Ziman, Melanie, Calapre, Leslie, Meniawy, Tarek M., Gray, Elin S., Beasley, Aaron B.

    Published in Scientific reports (13-02-2023)
    “…Circulating tumour cells (CTCs) are heterogenous and contain genetic information from the tumour of origin. They bear specific intra- and extra-cellular…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16

    Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection by Moore, Penny L, Ranchobe, Nthabeleng, Lambson, Bronwen E, Gray, Elin S, Cave, Eleanor, Abrahams, Melissa-Rose, Bandawe, Gama, Mlisana, Koleka, Abdool Karim, Salim S, Williamson, Carolyn, Morris, Lynn

    Published in PLoS pathogens (01-09-2009)
    “…We previously showed that HIV-1 subtype C viruses elicit potent but highly type-specific neutralizing antibodies (nAb) within the first year of infection. In…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies by Moore, Penny L, Sheward, Daniel, Nonyane, Molati, Ranchobe, Nthabeleng, Hermanus, Tandile, Gray, Elin S, Abdool Karim, Salim S, Williamson, Carolyn, Morris, Lynn

    Published in Journal of Virology (01-05-2013)
    “…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  20. 20